Agarwal Vijay, Subash Anand, Nayar Ravi C, Rao Vishal
Department of Medical Oncology, HCG Cancer Centre, Bangalore, India.
Department of Head and Neck Oncology, HCG Cancer Centre, Bangalore, India.
J Surg Oncol. 2019 May;119(6):685-686. doi: 10.1002/jso.25387. Epub 2019 Jan 30.
Epidermal growth factor receptor (EGFR) is overexpressed in 90% to 100% of squamous cell carcinoma of the head and neck (SCCHN). The overexpression of EGFR and its ligand transforming growth factor is associated with poorer survival. EGFR inhibitors such as Cetuximab (Erbitux) have shown a significant antitumoral effect in SCCHN and has improved locoregional control and as well as survival. Even though there was some success with Cetuximab, work with other EGFR inhibition has not been very fruitful and not really shown any promise. Mechanism of action of Cetuximab could be immune-mediated rather than EGFR inhibition and EGFR may not necessarily be a therapeutic target in SCCHN.
表皮生长因子受体（EGFR）在90%至100%的头颈部鳞状细胞癌（SCCHN）中过表达。EGFR及其配体转化生长因子的过表达与较差的生存率相关。西妥昔单抗（爱必妥）等EGFR抑制剂在头颈部鳞状细胞癌中显示出显著的抗肿瘤作用，改善了局部区域控制以及生存率。尽管西妥昔单抗取得了一些成功，但其他EGFR抑制的研究成果并不丰硕，也未显示出任何前景。西妥昔单抗的作用机制可能是免疫介导的，而非EGFR抑制，并且EGFR不一定是头颈部鳞状细胞癌的治疗靶点。
